Skip to main content
. 2018 Jan 31;169(2):257–266. doi: 10.1007/s10549-018-4682-5

Fig. 4.

Fig. 4

Disease-free survival (a) and overall survival (b) rates between patients with stage II HR(−)/HER2(−) tumors and those with stage III HR(+)/HER2(−) tumors using the prognostic staging system